Supplementary Figure Legends

Supplementary Figure S1: Flow cytometry gating strategy and representative results in the infected ear dermis. (A) Representative flow cytometry data for granulocytes (GR1$^{hi)}$), inflammatory monocytes (Ly6C^{hi}CD11b$^+$) and monocyte-derived myeloid cells (Ly6C$^-$CD11b$^+$) and Sca-1 expression. **(B)** Representative flow cytometry data fo CD3ε$^+$ CD4$^+$ and CD3ε$^+$CD8$^+$ T cell subsets. All percentages are calculated on the parent population (indicated at the top of the column).

Supplementary Figure S2: Flow cytometry gating strategy and representative results for BM stem/progenitor cell subsets. (A) Gating strategy and representative flow cytometry data for a naïve mouse, demonstrating the identification of Lin$^-$ Sca1$^+$ cKit$^+$ (LSK) stem/progenitor cells and their different subsets according to CD150, CD48, and CD135 expression (MPP3, MPP2, LMPP and LT-HSC) in the bone marrow. The same strategy was also used for the spleen. **(B)** Representative flow cytometry data for infected mice on day 1, day 7, and day 56 post-infection. All percentages are calculated on live singlets.

Supplementary Figure S3: Flow cytometry gating strategy and representative results for myeloid cells in BM and spleen. (A) Gating strategy and representative flow cytometry plots of naïve and infected mice (day 56), demonstrating the identification of granulocytes (GR1^{hi}), and mature monocytes (Ly6C^{hi}CD11b$^+$) in the bone marrow. **(B)** Representative flow cytometry plots and gating strategy of naïve and infected mice (day 56), demonstrating the identification of granulocytes (GR1^{hi}), inflammatory monocytes (Ly6C^{hi}CD11b$^+$), alternative monocytes (Ly6Cl$^{LO/-}$ CD11b$^+$), and monocyte-derived myeloid cells (Ly6C$^-$ CD11b$^+$ MHC-II$^+$) in the spleen. All percentages are calculated on live singlets.

Supplementary Figure S4: Flow cytometry gating strategy and representative results for red blood cells and platelets. Gating strategy and representative flow cytometry plots of naïve and infected mice (day 56) and for platelets (CD41$^+$) and the different stages of red blood cell differentiation (based on CD71 and Ter119 expression) in **(A)** the bone marrow and **(B)** spleen. Percentages for platelets refer to total CD45- cells, while those for erythroid cells are calculated as percentage of total erythroid cells (all four stages).

Supplementary Figure S5: Lymphocytes in the bone marrow. (A) The number of cells within the CD48$^+$CD150$^-$CD135$^+$ MPP4 subset of hematopoietic progenitor cells in bone marrow at different times post-infection. **(B)** Number of CD19$^+$ B lymphocytes, **(C)** CD4$^+$ CD3ε$^+$ T lymphocytes, and CD8$^+$ CD3ε$^+$ T lymphocytes in BM on day 56 post-infection. Graphs represent are the mean ± SEM of n=13, n=11, n=11 and n=15 mice per group (*Lm*Fn vs *Lm*Sd) at 1,7, 14 and 56 days post-infection, respectively. * *P*<0.05 comparing infection with *Lm*Fn vs. *Lm*Sd at a given time point and † *P*<0.05 comparing infected groups (*Lm*Fn or *Lm*Sd) to naive control mice. The results are compiled from at least 4 independent experiments for each time point. **(D)** Gating strategy and representative flow cytometry data for naïve and infected mice (day 56). The percentages are calculated on live singlets (CD19$^+$ cells, CD3ε$^+$ cells) or on the parent population (B and T cell subsets).

Supplementary Figure S6: Myeloid colony-forming units in the bone marrow. Total number of colonies (light grey, black, white) and monocytic colonies (dark grey) per 1x10^4 bone marrow cells isolated from naïve mice or on day 56 post-infection. Bars represent mean + SEM of four mice per group.